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INTRODUCTION

“Providers wrote nearly a quarter of a billion opioid prescriptions in 2013; enough
for every American to have their own bottle of pills.” 1 This high number of pills per
American has started a tidal wave of problems that is sweeping across America.
However, it is the drug manufacturers that are responsible for these growing problems.
The opioid epidemic that is striking the nation is drawing serious attention and raising
questions about what to do to solve it. While it is a nationwide problem, it has also
hugely affected Ohio. These drugs are no longer those that can be associated with the
common image of a ‘drug addict;’ they are being found far more frequently in high
schools, affluent neighborhoods, and families of all races, cultures, religions and
income statuses alike. 2 The key to stopping this problem lies within the prescription
drug community. Prescription drug manufacturers have a major influence on the
number of pills being prescribed by doctors. In 2016, 631 million opioid pills, such as
OxyContin, Percocet, Vicodin, Lortab, and Percodan were given out, and this number
showed a 20.4% decrease since 2012. 3
These national problems target families and people all over the country, including
Daniel,4 who went to high school in a small affluent town right outside Cleveland,
Ohio. He was in high school the first time he began using pain pills. What started out
as pain medication after an injury, quickly led Daniel to take illegal means to obtain
more pain medication. Unbeknownst to his family and friends, this is how Daniel’s
problem began. He went off to college after graduating high school, and that is when
it became very apparent to his family he was having problems. After plummeting
grades and learning he had sold nearly everything he owned, his parents had no choice
but to bring him home. It was not until Daniel got home that his family was really able
to understand the severity of this problem. Not only was he selling his own belongings
1

IMS Health, National Prescription Audit (NPATM). Cited in internal document: Preliminary
Update on Opioid
Pain Reliever (OPR) Prescription Rates Nationally and by State: 2010-2013.
2

David Armstrong, 52 weeks, 52 faces, STAT (Dec. 20, 2016),
https://www.statnews.com/feature/opioid-epidemic/obituaries/; see also Vince Grzegorek,
Another Brutally Honest Obituary From a Family Who Lost a Loved on to a Heroin
Overdose, SCENE & HEARD (May 5, 2017), https://www.clevescene.com/scene-andheard/archives/2017/05/05/another-brutally-honest-obituary-from-a-family-who-lost-a-lovedone-to-a-heroin-overdose; see also Dan Horn and Terry DeMio, Seven Days of Heroin; This is
what an Epidemic Looks Like, CINCINNATI.COM (Sept. 10, 2017),
https://www.cincinnati.com/pages/interactives/seven-days-of-heroin-epidemic-cincinnati/; see
also Jen Steer, Local man Shares Emotional Account of Daughter’s Heroin Overdose, FOX 8
NEWS (Dec. 27, 2017), http://fox8.com/2017/12/27/local-man-shares-emotional-account-ofdaughters-heroin-overdose/.
3
4

OHIO AUTOMATED RX REPORTING SYSTEM ANNUAL REPORT (2016).

Busch Funeral Home, Obituary for Daniel Wolanski, (April 20, 2015),
http://buschfuneral.tributes.com/obituary/show/Daniel-Joesph-Wolanski-102411062 (daniel
was a high school kid, growing up in an affluent neighborhood, right outside of Cleveland,
went to a nationally ranked high school, and would go on to attend a well-known College,
University of Cincinnati. This story is significant, important and relevant to this topic because
it shows that this epidemic is harming and reaching further than just our visualizations of
“drug addicts” or people who are using drugs, but reaching into high schools, middle schools,
colleges, and tearing apart families).
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for pills, but he was stealing from his family and selling whatever he could get his
hands on from the ones he loved just to get his next round of pills. 5 With the help of
his family, Daniel agreed to go to a rehabilitation facility and get the help he so
desperately needed.
After completing his program, he stayed clean for a period of time, but eventually
fell right back into his old habits, except this time, it became deadlier because the pills
were no longer affordable. Daniel turned to heroin, a much cheaper and stronger
option, and it was not until his first overdose that his family realized the true battle he
had ahead of him. Daniel was denied rehabilitation treatment the next time around
because health insurance refused to pay and the cost was far more than the family
could afford out of pocket. 6
Unfortunately for Daniel, this was happening at a time when heroin was being
mixed and cut with a new drug called fentanyl, a much stronger drug than heroin and
usually kept quiet when it is mixed in with heroin. Shortly thereafter, when Daniel
was only 24 years old, he was found dead in his apartment, and it was determined that
this occurred from an accidental overdose of heroin. This is unfortunately the tragic
yet common ending we are seeing in today’s society. What started out as prescription
pills for an injury, eventually lead to the untimely death because of addiction.
The opioid epidemic that Ohio is faced with today is taking the lives of people
across all age ranges.7 Between 2014 and 2015, Ohio had the greatest number of opioid
related deaths in the nation – with 1 in every 14 deaths from opioids in the United
States occurring in the state. 8 With these alarming numbers, states like Ohio, that are
5

NATIONAL INSTITUTE ON DRUG ABUSE, Principles of Drug Abuse Treatment for Criminal
Justice Populations – A research-based guide, (“Individuals who use illicit drugs are more
likely to commit crimes, and it is common for many offenses to be committed by individuals
who had used drugs or alcohol prior to committing the crime, or who were using at the time of
the offense”), https://www.drugabuse.gov/publications/principles-drug-abuse-treatmentcriminal-justice-populations/introduction.
6

AMERICAN ADDICTION CENTERS, Heroin Addiction and Treatment, (rehabilitation from
heroin addiction uses medical detox, however, most heroin users want to be free of drugs upon
arrival and tend to rush the process, causing a relapse, or they will complete the medically
assisted detox, but have no way of dealing with the addiction once they leave treatment, and
then end up relapsing again), https://americanaddictioncenters.org/herointreatment/#The%20Best%20Way%20to%20Treat%20Heroin%20Addiction (last updated
Sept. 4, 2018).
7

Elizabeth Llorente, Opioid Addiction Crisis spurs brutal Candor in Obituaries, FOX NEWS
(May 14,2017), (a 23-year-old man from Staten Island, New York dies from an overdose),
http://www.foxnews.com/health/2017/05/14/opioid-addiction-crisis-spurs-brutal-candor-inobituaries.html; see also Shelly Bradbury, PITTSBURGH POST-GAZETTE (May 4, 2017) (an 11
year-old girl dies from a heroin overdose), http://www.postgazette.com/news/overdosed/2017/05/04/11-year-old-girl-overdoses-heroin-BeechviewPittsburgh-Narcan/stories/201705040162; see also Pat Grossmith, Heroin Overdoses take
Their toll in NH’s Largest City, UNION LEADER NEW HAMPSHIRE (Sept. 23, 2015), (the oldest
fatality due to a heroin overdose was a 51-year-old man),
http://www.unionleader.com/Heroin_overdoses_take_their_toll_in_NHs_largest_city_ (all of
these examples show the significance of this epidemic. It is not only affecting those we
consider “drug addicts,” but it is ravaging through the young and the old alike, all across the
country).
8

THE HENRY J. KAISER FAMILY FOUNDATION OVERDOSE DEATHS, (2014-2015); see also
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being hit hardest with this problem, are looking for the best solutions to decrease these
numbers. Ohio can be found at the top of that list, among other states, aggressively
looking for ways to combat this terrible but growing problem.
On May 31, 2017, Ohio Attorney General Mike DeWine decided to take a step in
the right direction of fighting the epidemic. DeWine brought the first of many lawsuits
against five top drug pharmaceutical companies. 9 The five companies are, Purdue
Pharma, Teva Pharmaceutical Industries, Cephalon, Inc., Janssen Pharmaceuticals,
and Endo Health Solutions Inc. 10 There are several counts being raised against the
pharmaceutical companies, but only the counts for deceptive marketing practices are
relevant for this Note. 11 This charge is particularly important here because Attorney
General DeWine states that these deceptive marketing practices are one of the leading
causes of this serious opioid epidemic. 12 This lawsuit has in turn prompted several
other states to follow suit.13 The trend of bringing these lawsuits shows the willingness
of states to recognize the problem and the want of these states to hold the correct
entities accountable. 14 New York Attorney General Eric Schneiderman stated, “For
millions of Americans, their personal battle with opioid addiction did not start in a
back alley with a tourniquet and syringe, they got hooked on medicine they were
prescribed for pain or that they found in a medicine cabinet.” 15 With law suits
becoming more prevalent, it is showing the willingness of states to accept and want to
hold those who are responsible accountable: the big drug pharmaceutical companies.
In doing so, any entity bringing a lawsuit will have to overcome an exception, that
exists under Products Liability Law, the Learned Intermediary Doctrine.
Under Federal and State law, there is an exception that exists, called the Learned
Intermediary Doctrine. This exception is one which can absolve the drug
manufacturers of liability from any misconduct that might be found and transfer that

OHIO DEPARTMENT OF HEALTH, Drug Overdose Report (in 2013, Ohio had 2,110 deaths
unintentional drug overdoses), https://www.odh.ohio.gov//media/ODH/ASSETS/Files/health/injury-prevention/odhnews2013DrugOverdoseData.pdf?la=en.
9

Complaint, State of Ohio v. Purdue Pharma, et al., No. 17CI000261.

10

Id.

11

Complaint at 66, State of Ohio v. Purdue Pharma, et al., No. 17CI000261.

12

Id.

Colin Dwyer, Ohio Sues 5 Major Drug Companies For ‘Fueling Opioid Epidemic’, NPR
(May 31, 2017) (Ohio followed Alabama in filing a law suit),
https://www.npr.org/sections/thetwo-way/2017/05/31/530929307/ohio-sues-5-major-drugcompanies-for-fueling-opioid-epidemic; see also Jackie Borchardt, Ohio Opioid Lawsuit
against 5 Pharma Companies: 6 Things to Know, CLEVELAND.COM (May 31, 2017) (Cherokee
nation in Oklahoma also followed Ohio’s lead in filing a law suit),
http://www.cleveland.com/metro/index.ssf/2017/05/ohios_opioid_lawsuit_against_5.html.
13

THE TWO WAY

14

Yuki Noguchi, 41 States to Investigate Pharmaceutical Companies Over Opioids, NPR THE
TWO WAY (September 19, 2017)
https://www.npr.org/sections/thetwoway/2017/09/19/552135830/41-states-to-investigatepharmaceutical-companies-over-opioids.
15

Id.
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liability to any treating physician. 16 This exception is extremely relevant to this topic
because it is the way many drug manufacturers were able to avoid being held
responsible in the past. This Note proposes that with the current pending lawsuit in the
State of Ohio, an exception to the Learned Intermediary Doctrine should be
introduced. This Note will begin with a discussion of opioids and how these drugs
have become such an aggressive problem in a very short amount of time in Ohio. Part
II will talk about the role the government can play and the role the drug manufacturers
have played and continue to play in the availability of opioids. It will discuss the effect
these drug pharmaceutical companies have had on this problem and have had in
increasing this problem. Part II will also discuss why this is a problem and why this
problem matters. Further, it will talk about the steps that have already been taken by
the Ohio Legislature to combat the opioid problems. Finally, it will delve into a
discussion of what this current lawsuit means for fighting and decreasing the opioid
problem and how it will directly affect the heroin epidemic in Ohio.
II. BACKGROUND
While this is a national problem, Ohio has been one of many states hit hard by this
problem.17 In 2010, Ohio declared a public health emergency due to rising overdose
deaths.18 “In 2016, unintentional drug overdoses caused the deaths of 4,050 Ohio
residents, which was a 32.8% increase compared to 2015.” 19 Although prescription
opioid-related deaths have declined again, from 667 in 2015 to 564 in 2016, 20 the
damage from the prescription pills has already been done and continues to ravage
through the most unsuspecting homes and families. According to a study conducted
by the Center for Behavioral Health Statistics and Quality, in August of 2013, three
out of four new heroin users reported first abusing prescription opioids before
beginning to use heroin. 21 While these unintentional drug overdoses include heroin, 22
the lawsuit brought by the state of Ohio relates the heroin epidemic directly to the
misrepresentation of the effects of treating chronic pain with opioid pain killers. 23 The
lawsuit intends to hold the drug manufacturing companies liable for these
misrepresentations that were made, which in turn lead to the heroin epidemic that is
faced by so many today.

16

Ohio Rev. Code Ann. §2307.76(C) (West 1988).

17

AMERICAN ADDICTION CENTERS, supra note 6.

18

Ohio Attorney General Complaint against Pharmaceutical Companies: The State of Ohio is
suing 5 major drug pharmaceutical companies for allegedly misrepresenting their products and
for false advertising, as a violation of the law under the products liability law in Ohio, and
under Fraud in Ohio.
19

OHIO DEPARTMENT OF HEALTH, Drug Overdose Report (2016).

20

Id.

21

Pradip K. Muhuri Et Al., Association of Nonmedical Pain Reliever Use and Initiation of
Heroin Use in the United States, SAMHSA (Aug. 2013),
https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use2013.htm.
22

Id.

23

Complaint at 29, State of Ohio v. Purdue Pharma, et al., No. 17CI00026.
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This section will begin with a brief discussion of opioids and what they are, the
epidemic that is happening, and why it is important for the government to step in and
take action. Next, there will be a discussion on the main role the drug manufacturers
play in this epidemic. Also, this section will discuss the steps taken to try and hold
these pharmaceutical companies liable. Finally, it will end with why the proposed
solution is the best way to begin to get this epidemic under control.
A. What Are Opioids?
Opioids are a class of drugs that are usually taken for pain relief. 24 There are natural
opioids and then there are manmade synthetic opioids. 25 Natural opioids come from
the poppy plant, while synthetic opioids are created in a lab. 26 Heroin, fentanyl and
OxyContin are the three most commonly known synthetic opioids because they are
manmade as opposed to being natural. 27 “Prescription opioids are powerful painreducing medications that include prescription oxycodone, hydrocodone, and
morphine.” 28 Opioids work by interacting with the opioid receptors that are on nerve
cells in the body and brain. People who take opioids for long periods of time are known
to have a higher risk of becoming addicted to the pills. 29 These opioid addictions
quickly lead to heroin addictions because heroin is more readily available. 30 Heroin is
also far less expensive than any prescription opioids that individuals take. 31 Heroin is
also considered to be a better option because users and addicts no longer have to go to
their doctor to get a prescription. 32 The effects that opioids have are clear, but it is not
always clear why these drugs are such a danger and so harmful to many people in
society.

24

NATIONAL INSTITUTE OF DRUG ABUSE, Opioids, (Nov. 2018),
https://www.drugabuse.gov/drugs-abuse/opioids.
25

Casa Palmera Staff, What Drugs are Opiates?, CASA PALMERA (Nov. 17, 2016),
https://casapalmera.com/blog/what-drugs-are-opiates/.
26

Id.

27

Id.

U.S. FOOD AND DRUG ADMINISTRATION, Opioid Medications, U.S. DEP’T HEALTH
(last updated June 14, 2018),
https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337066.htm.
28

AND H UM. SERVICES
29

NATIONAL INSTITUTE OF DRUG ABUSE, Opioids https://www.drugabuse.gov/drugsabuse/opioids.
30

OHIO PRESCRIPTION DRUG ABUSE TASK FORCE; OHIO SUBSTANCE ABUSE MONITORING
NETWORK (2008); see also AMERICAN SOCIETY OF ADDICTION MEDICINE (“94% of respondents
in a 2014 survey of people in treatment for opioid addiction said they chose to use heroin
because prescription opioids were ‘far more expensive and harder to obtain.’”),
https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-factsfigures.pdf.
31

OHIO PRESCRIPTION DRUG ABUSE TASK FORCE; OHIO SUBSTANCE ABUSE MONITORING
NETWORK, supra note 30.
32

Id.
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Why Are They Harmful?

Opiates are so harmful because of the way they interact with the brain. Opiates
create endorphins in the brain, which in turn, lead to the user experiencing a rush of
emotions. 33 This rush of emotions is due to endorphins releasing dopamine, what is
often known as the ‘feel-good’ emotion. 34 This process does not become an issue
unless these drugs are taken over a long period of time. 35 The brain eventually stops
producing endorphins naturally, so once the drugs are no longer being taken, the user
no longer experiences those positive feelings and emotions.36 Without taking the
drugs, the dopamine levels in the brain drop significantly, so the person taking the
drugs is not experiencing this rush of emotion anymore. 37 “The body quickly builds
up a tolerance to opioids, so it takes more and more of the drug to create the same
pain-relieving and euphoric effects.”38 Dr. Nora Volkow compared the effects of
taking opioids with bad steering, “Your steering wheel does not work properly. So not
only are you actually accelerating with intense desire and motivation to get the drug,
you are not able to self-regulate and say, ‘If I take the drug, I will end up in jail.’” 39
This analogy helps to explain the dependency, because the brain is no longer
producing these endorphins. A person who is addicted will do anything just to have
that experience again, without considering the consequences. 40 The reactions that
occur in the brain can help explain why people turn from opioids to heroin.
2.

What Is Heroin, and Where Does it Come From?

The drug heroin is at the heart of this epidemic and is bringing light to this
epidemic, so it is important for this Note to explain the role of heroin. Heroin is an
opioid drug made from morphine. 41 Heroin can come in different forms and can be
ingested in different ways, but the main way people use heroin is by injecting it with

Michael’s House, Why Are Opiates so Addictive? (2017),
http://www.michaelshouse.com/opiate-rehab/why-are-opiates-so-addictive/.
33

34

Katelyn Newman, A Personal Look at a National Problem, US NEWS AND WORLD REPORT
(May 18, 2017), https://www.usnews.com/news/national-news/articles/2017-05-18/the-opioidepidemic-a-personal-look-at-a-national-problem.
35

Id.

36

Id.

37

Newman, supra note 34.

38

Id.

39

The Associated Press, Science Say: Why are Opioids so Addictive?,
https://www.apnews.com/7615878f9f40487593d99f02e68d96ee/Science-Says:-Why-areopioids-so-addictive?
40
41

Michael’s House, supra note 33.

NATIONAL INSTITUTE ON DRUG ABUSE, What is Heroin? (2018)
https://www.drugabuse.gov/publications/drugfacts/heroin; see also Medline Plus, Morphine,
U.S. N ATIONAL LIBRARY OF MEDICINE (June 15, 2017), (morphine is used to treat severe pain,
and only used when there is no other way to treat the pain, morphine is highly regulated by the
doctor or physician prescribing it because of how strong it is and how many side effects it
causes), https://medlineplus.gov/druginfo/meds/a682133.html#why.
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a syringe. 42 The effects of heroin are very similar to that of the effects of prescription
drug use; people using heroin typically report a feeling of euphoria.43 Euphoria results
because heroin affects the brain the same way prescription drugs do, which is binding
to the opioid receptors in order to increase the feelings involved with pain and
pleasure. 44
Heroin is not a drug that is prescribed by doctors, it is a drug that is found on the
streets. More commonly, it is known to be found on the dark net’s “black market.”
The dark net “is a constellation of sites and services that can be accessed through a
special browser, which routes online traffic so it’s much more difficult to identify
where it originally came from.” 45 In July 2017, one of the largest online black market
drug websites, known as AlphaBay, was taken down by the FBI. 46 This website was
being run not only nationally, but internationally, and was housing more than 250,000
listings for illegal drugs.47 It was estimated that previous to AlphaBay being shut
down, there were about 238 vendors advertising for the sales of heroin. 48 While these
type of online black market sites are very common, there are also physical places that
people can go to obtain drugs illegally. For example, in August 2017, a medical clinic
was closed in California for sending dangerous and addictive pills to the black
market.49 While these are only a few examples, instances like these are happening all
over the United States and even worldwide. 50
These kinds of statistics beg the question: how are these pills, which a patient needs
a prescription to obtain, so readily available on the black market? Generally, there is
one term that can describe this influx of prescription pills – diversion – which is most
common at the patient level. 51 Diversion at the patient level consists of patients who
42

Id.

43

Id.

44

Id.; see also NATIONAL INSTITUTE ON DRUG ABUSE, What are the immediate effects of heroin
use? (Jan. 2018), https://www.drugabuse.gov/publications/research-reports/heroin/what-areimmediate-short-term-effects-heroin-use (abusers report a “rush” feeling, and this “rush”
feeling generally controls how much of the drug is taken in by the user and how quickly they
experience the rush).
45

Kif Leswing, The FBI just took down AlphaBay, Online Black Market for Drugs, BUSINESS
INSIDER (Jul. 20, 2017), http://www.businessinsider.com/alphabay-online-black-market-takendown-silk-road-2017-7.
46

Id. see also Joseph Goldstein, Arrest in U.S. Shuts Down a Black Market for Narcotics (Oct.
2, 2013), (Silk Road was another website run on the dark net, was home to more than 100,000
customers and was also responsible for the selling of black market drugs),
https://www.nytimes.com/2013/10/03/nyregion/operator-of-online-market-for-illegal-drugsis-charged-fbi-says.html.
47

Id.

48

Id.

Thom Mrozek, UNITED STATES ATTORNEY’S OFFICE; CENTRAL DISTRICT OF CALIFORNIA
(Aug. 3, 2017), https://www.justice.gov/usao-cdca/pr/operators-bogus-medical-clinicscharged-conspiracy-divert-massive-amounts-prescription.
49

50

Leswing, supra note 45.

51

Id.
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once needed pain medication but are no longer in need of it and are sitting on pills,
family members who find the pills and dispose of them, or patients who do not actually
need the pain medication but are “doctor shopping.” 52 Doctor shopping is a commonly
used term today to describe a situation where a patient will go from doctor to doctor,
trying to get a prescription for pain medication filled. 53 Once they have obtained the
prescription, they sell it. 54 As discussed below, part of stopping the epidemic is
stopping the flow of prescription drugs illegally onto the black market.
3.

Why This Issue is Important to the Government

This problem is important to the government because it is now not only affecting
adults, but it is also reaching younger individuals each and every year. “After
marijuana and alcohol, prescription drugs are the most commonly misused substances
by Americans age 14 and older.” 55 The problems with addiction are soaring to
unbelievable heights. While this is a vast problem throughout the United States, it
would be best dealt with on the state level so that each state can make adjustments
based on the specific problem in that state. There have been several attempts to remedy
the problem, but nothing has been as influential as going directly to the source of the
problem: holding the drug manufacturing companies, those responsible for the
prescription drugs in the first place, accountable.
Specifically in Ohio, in 2015, House Bill 4 was passed, giving broader access to
the drug Naloxone. 56 Naloxone is a drug known to reverse the effects from an opioid
overdose, as long as it is dispensed in time. 57 A survey taken counting the
administration of Naloxone found that there were about “11 administrations per day
of the drug in 2003, and about 29 administrations of the drug per day in 2012.” 58 There
is a clear correlation between the increase in the administration of naloxone and the
increase in overdoses. Naloxone’s main use today is for the treatment of an overdose
and to help reverse an overdose. 59 But, as previously noted, the overdose deaths have
only continued to rise. 60 Even though Naloxone is helping to reverse specific
incidences of overdoses, it is not substantially decreasing the overdoses, further

52

Eric Boodman, Opioid Crisis Fueled by Prescriptions from Family Doctors and Internists,
STAT (Dec. 14, 2015), https://www.statnews.com/2015/12/14/opioid-crisis-fueledprescriptions-family-doctors-internists/.
53

Id.

54

Id.

55

NATIONAL INSTITUTE ON DRUG ABUSE FOR TEENS, Prescription Drugs, (March 2017),
https://teens.drugabuse.gov/drug-facts/prescription-drugs.
56

Ohio House Passes Legislation Expanding The Use of Naloxone | The Ohio House of
Representatives.
57

Id.

58

OHIO MENTAL HEALTH & ADDICTION SERVICES, Naloxone Administration in Ohio 20032012 (2012), http://mha.ohio.gov/Portals/0/assets/Research/Reports/2013-no2-naloxoneepidemiological%20report.pdf.
59

Leswing, supra note 45.

60

Dwyer, supra note 13.
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illustrated by the continuing rise in annual overdose deaths. 61 This is just furthering
the need for the government to step in and help.
A Sheriff in Butler County has recently refused to allow his officers to carry
Naloxone. 62 Specifically, Sheriff Richard K. Jones, will not allow his officers to carry
Naloxone due to the expense of the drug and due to the amount of repeated
administration to the same individuals.63 This has come across to many in the media
as shocking because of the lives that Naloxone has helped save, however, Jones insists,
“all we’re doing is reviving them, we’re not curing them.” 64 This is a belief that is held
by many who are skeptical of the increased availability of Naloxone. 65
State governments, as well as the federal government, acknowledge that there is a
growing problem, but none of the solutions proposed have gone far enough to put a
significant halt on this epidemic we are seeing, as the overdose deaths are still steadily
increasing.66 For this reason, there needs to be stronger options in order to stop this
epidemic from increasing.
4.

The Role Of The Food And Drug Administration

The Food and Drug Administration (“FDA”), created in 1848, is the oldest
consumer protection agency within the United States Government. 67 The FDA was
broadly known as a consumer protection agency, much of how we think of it today,
but it did not have only one specific area of focus. 68 As the times change throughout
the nation, the FDA changes along the way. 69 Today, however, the FDA’s drug review

61

Id.

Ohio Sheriff Says Officers Won’t Carry Narcan, NBC NEWS (July 7, 2017),
https://www.nbcnews.com/storyline/americas-heroin-epidemic/ohio-sheriff-says-hisoverdosing-ohioans-my-guys-have-no-n780666.
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city purchased over 7,000 doses of naloxone, which came out to be a total of $243,560 in
order to combat the overdose calls they will receive).
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Siemaszko, supra note 62 (Board Member Debbie Walsh opposed allowing Narcan in
Public schools in Akron; and was met with several others who agreed with her.); see The
Associated Press, Just Say No to Narcan? CBS NEWS (September 26, 2016), (people have
expressed frustration about rescuing addicts who often immediately resume using the
potentially deadly drug). https://www.cbsnews.com/news/just-say-no-to-narcan-heroinrescue-efforts-draw-backlash/.
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Dwyer, supra note 13.
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https://www.fda.gov/AboutFDA/WhatWeDo/History/.
67

68

Id.

69

Id.

120

JOURNAL OF LAW AND HEALTH

[Vol. 32:1]

process ensures that drugs undergo very extensive safety, quality, and effectiveness
evaluations before they are able to be sold to the public on the market. 70
Another reason it is important to the government is because the FDA is in charge
of allowing these kinds of drugs into society, as well as determining the guidelines
and precautions for certain drugs.71 The mission of the FDA is to protect the public
health by assuring safety, among other things, of human and veterinary drugs. 72
Further, in 2016, the FDA stated that opioids should only be used to treat pain as a last
resort, which was the opposite of what drug manufacturers were advertising. 73 Since
these drugs fall under the control of the FDA, which is a governmental agency, that is
another reason the government is, and should be, involved in this growing problem.
B. What Role Are Drug Pharmaceutical Companies Playing?
The role drug pharmaceutical companies play in this problem is obvious:
pharmaceutical companies have played a vital role in the increase of opioid related
overdoses across the country. 74 Drug pharmaceutical companies have been falsely
reassuring and representing not only to those in the medical field, but also to patients
directly, that opioid pain relievers are safe to use for chronic pain, without risk of
addiction.75 As alleged in the lawsuit by Ohio Attorney General, Mike DeWine, each
of the drug manufacturing companies have been promoting the utilization of opioids
for chronic pain through their sales representatives. 76 Even after the problems were
made public and continued to surface, DeWine alleges there was never an attempt to
correct the falsely given information and that the drug pharmaceutical companies
simply did nothing. 77 These companies increased their budget, spending, and the time
their drug representatives were spending with doctors. 78 These practices have been
going on since the late 1990s and have led to the epidemic we are faced with today. 79

70

Michelle Meadows, Promoting Safe & Effective Drugs for 100 Years, FDA CONSUMER
MAGAZINE, Jan.-Feb. 2006.
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Douglas C. Throckmorton, M.D., The Public Health Role of Drug Regulation in the US,
U.S. FOOD AND DRUG ADMINISTRATION (March 20, 2017),
https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandToba
cco/CDER/UCM550079.pdf.
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Complaint at 43, State of Ohio v. Purdue Pharma, et al., No. 17CI000261 (From the early
1990’s until today, regardless of any regulation put in place by the FDA, advertisements and
selling points for drug manufacturers stated that opioids were safe for long-term use to treat
chronic pain).
74NATIONAL INSTITUTE ON DRUG

ABUSE FOR TEENS, opioid overdose crisis (June 2017),
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-crisis#one.
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Complaint at 15, State of Ohio v. Purdue Pharma, et al., No. 17CI000261; see also Id.
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With this, several states are starting to point to the drug manufacturing companies as
the ones to blame, and rightfully so. 80 While other options have been tried, and have
failed, this is one more attempt to get this epidemic under control.
Recently, in September 2017, “41 state attorneys general announced they were
expanding their investigation into companies that manufacture and distribute opioid
pain killers.”81 Ohio, specifically, brought a lawsuit seeking damages from five major
pharmaceutical companies that manufacture opioid pain pills.82 This lawsuit is seeking
damages for the pain and suffering, loss of life, and overall punitive damages for the
negative effects of the pharmaceutical companies’ advertising misrepresentations. 83
However, this is not the first time many of these companies are being questioned or
even engaging in settlements for their misrepresentations. 84 Though there have been
several settlements, the pattern of misleading advertising and false representations has
not ceased. 85
In the past, Cephalon, one of the drug manufacturing companies named in the
lawsuit by the state of Ohio, pled guilty to a violation of the Federal Food, Drug and
Cosmetic Act (“FDCA”) for misleading the promotion of three (3) drugs. 86 Part of this
misleading promotion that Cephalon was doing involved the drug Actiq. The company
ordered sales representatives to try and convince doctors to use the drug for certain
unapproved uses. 87 The manufacturing company agreed to pay $425 million for the
violation of the FDCA, 88 all the while still continuing to do what it pled guilty for in
the past.89 While the company ceased to use that sales strategy with Actiq after the
settlement occurred in 2003, Cephalon was still pushing for the long-term use of

https://www.pbs.org/newshour/show/opioid-addiction-biggest-drug-epidemic-u-s-historyhowd-get.
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companies and the national addiction epidemic).
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opioids to treat chronic pain. This exemplified how a settlement did not deter the
behavior.90
Purdue Pharma also reached a settlement agreement in federal court in the Western
District of Virginia, paying upwards of $600 million in fines for misleading regulators,
physicians, and patients about the risks that are associated with taking OxyContin. 91
Specifically, Purdue Pharma underestimated and underreported the “risk of addiction
and the drug’s potential to be abused.” 92 While these are only two examples, it is clear
that these pharmaceutical companies have been aware and put on notice in the past
that their misleading advertisements and misrepresentations have caused serious harm.
This demonstrates the need for a more aggressive way of handling these companies.
Furthermore, in the past it has been hard for individuals to hold pharmaceutical
companies responsible for the adverse effects they were receiving due to the use of
opioids. 93 Generally, a state is going to be more sympathetic because a state can never
be to blame for abusing pills, whereas individuals can be. 94 In many instances, people
perceive that the abuse of opioids by the user as his or her problem because the user
did not appropriately use the medication and thus caused their own problems.95 This
belief makes it very difficult to show the pharmaceutical companies’ responsibility
and the role the pharmaceutical companies are actually playing. 96 Lars Noah, a
professor of law at the University of Florida, has stated, “doctors, not consumers, were
the ones targeted by the aggressive marketing campaigns undertaken by
pharmaceutical companies, so it can be difficult to link consumer deaths with
aggressive marketing.” 97 This will be discussed later in this Note, but this is essentially
the reasoning behind the Learned Intermediary Doctrine since doctors are generally
the ones being targeted by these pharmaceutical companies.
1.

Drug Representatives Provide Information to the Medical Community

Drug representatives are employed by pharmaceutical companies to sell products,
and they are also in charge of educating and informing physicians about their
products. 98 Drug representatives also work on a commission basis, so the incentive to
get a physician to purchase from them, over their competitors, goes beyond simply
90

Id.
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Meiser, Guilty Plea, OxyContin Maker to Pay $600 Million, THE NEW YORK TIMES,
BUSINESS DAY (May 10, 2017), http://www.nytimes.com/2007/05/10/business/11drugweb.html.
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A Day in the Life of a Pharmaceutical Sales Representative Med Reps, MEDICAL SALES 101
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promoting their products. 99 “These reps help to influence the physicians to prescribe
their specific drugs to the physician’s patients.” 100 This also means that these drug
representatives are giving the physicians the same information provided to the drug
representatives about their own products, which is provided to them by their own
companies. 101 If the pharmaceutical companies are giving out information that is
deceptive, that means their drug representatives are giving out that same misleading
information to the physicians.102 As alleged in the Ohio lawsuit, all of the
pharmaceutical companies were using deceptive advertising measures to get doctors,
as well as patients, to believe these pills were safe for long-term use when in fact they
were not.103 These drugs were being pushed in the face of the medical community as
a first option when in fact the FDA was pushing for these drugs to be used merely as
a last resort.104 The drug representatives are also responsible for getting physicians to
choose their company and their drugs over their competitors.105 It is no longer an easy
task to get that job done, so it requires these representatives to get more creative in
their selling tactics. 106 Selling tactics can and do involve making their specific product
more appealing to the physician than that of their competitor. 107 Misleading
information often comes from the need to make the product more appealing, more
reliable, or better than that of the competitor.
However, the medical community still relies entirely on the information provided
by the drug manufacturing companies’ drug representatives, so these creative selling
tactics were simply just a way to overshadow the drug representatives putting their
financial goals over their responsibility and duty owed to their consumers.108 One
study found that, in 2012, the pharmaceutical industry in the United States spent more
than $27 billion on drug promotion and more than $24 billion of that overall spending
went to marketing specifically to physicians.109 The dynamic between drug
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pharmaceutical companies due to this want and need to sell their product over others
has raised questions over the years about whether or not this is in fact ethical. 110
Attorney General DeWine also addresses the issue of “Key Opinion Leaders
(“KOLs”).” 111 These are groups of doctors who are paid by the drug companies to be
consultants on behalf of the drug companies and their products. 112 Often times, these
KOLs are invited to speak at continuing medical education (CME) conferences, which
are required for those in the medical field. 113 Specifically, “KOLs have written,
consulted on, edited, and lent their names to books and articles supporting chronic
opioid treatment.” 114 This becomes problematic because doctors are relying on the
information given by their peers as KOLs, when in fact, the KOLs’ support of the
drugs is due to receiving payments instead of actually promoting the health and wellbeing of patients. 115 This is similar to the paid endorsements we see each and every
day with athletes. They are promoting the product because they are being paid to do
so, not because they truly believe that the product is the best one on the market.
Another example we see of this is with lobbying within the government. Lobbyists are
fighting for their own interests, not because the interest they want is for the greater
good. The analogy is simple yet frightening. It has become even more obvious that
there is a problem with the relationship between drug representatives, drug
pharmaceutical companies, and physicians; it is time something is finally done.
However, with such challenging allegations already set forth, states are even further
challenged to try to hold drug pharmaceutical companies liable due to an exception
written within products liability law.
C. The Learned Intermediary Doctrine
Products liability law nationally, as well as in the state of Ohio, allows consumers
to bring a claim against a company or a manufacturer for injury or death resulting from
the way the product was designed or made, lack of warning, or lack of warranty. 116
While products liability laws apply to just about all products on the market, these laws
have recently been expanded to include medications as well as medical devices. 117
However, when it comes to medical drugs and medications, there is a special exception
that exists when it comes to holding drug manufacturers liable for prescription
Hneine Brax, et al., Association Between Physicians’ Interaction with Pharmaceutical
Companies and Their Clinical Practices, 4 PLOS 12 (2017) (of 19 studies done to look at the
different types of interactions between pharmaceutical companies and drs. found a consistent
association between interactions promoting a medication & increased proscribing rates
inappropriately), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391068/; see also Birendra
Kumar Mandal, et al., Relationship Between Doctors and Pharmaceutical Industry: and
Ethical Perspective 3 INT. J. PHARMACEUTICAL & BIOLOGICAL ARCHIVES 415-417 (2012),
file:///Users/lacyleduc/Downloads/2.Relationshipbetdoctorsandpharmaceuticalindustry.PDF.
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drugs.118 This exception is known as the Learned Intermediary Doctrine. 119 The
Learned Intermediary Doctrine has been recognized for almost 50 years and is now
recognized and applied in almost every jurisdiction nationwide. 120 The Learned
Intermediary Doctrine was first recognized in case law. 121 The case is from the 8th
Circuit in 1966, Sterling Drug, Inc. v. Cornish, where an action was brought against a
drug manufacturer for eye damage, and the plaintiff alleged that the damage was due
to the drug that was being taken. 122 The issue before the court was to determine
whether the drug manufacturer had a duty to warn the doctor of the potential side
effect of the drug.123 The lower court ultimately found that drug manufacturer did have
a duty to warn the doctor since they were aware of the potential side effect of this
drug.124 The court stated,
In this case, we are dealing with a prescription drug rather than a normal
consumer item. In such a case the purchaser’s doctor is a learned
intermediary between the purchaser and the manufacturer. If the doctor is
properly warned of the possibility of a side effect in some patients and is
advised of the symptoms normally accompanying the side effect, there is an
excellent chance that injury to the patient can be avoided. 125
The learned intermediary doctrine applies to manufacturers who normally would
owe a duty to the consumer but instead are precluded from liability because the
“learned intermediary” or the general physician has been given adequate warning
about the consequences. 126 This exception exists specifically when it comes to medical
drugs because a physician is said to be in the best position to discuss their patients’
needs and to give them the necessary warnings about prescriptions and treatment
options associated with them. 127 However, this again causes a huge problem that this
exception does not cover, which is when intentional incorrect information is being
provided to the physician. As shown in the examples stated above, Cephalon and
Purdue Pharma were able to reach settlements instead of properly being held
accountable for their misrepresentations. 128
118
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The Ohio Supreme Court held in Tracy v. Merrell Dow Pharmaceuticals Inc., that
“the physician has the duty to know the patient’s condition as well as the qualities and
characteristics of the drugs or products to be prescribed.” 129 In this case, the Estate of
Larry Tracy sued Merrell Dow Pharmaceuticals for the death of Tracy and alleged that
it was due to a known side effect of the Nicorette. 130 The Court found that the physician
in this case was participating in the study and was aware of the potential side effects
as well as the potential effect that they would have on certain patients.131 Because the
physician was aware of the potential side effects, it was enough to establish him as the
learned intermediary, and thus, shifting the blame from the drug company to the
physician.132 In Ohio, manufacturers of prescription drugs are precluded from liability
for failure to instruct or warn consumers so long as they instruct and warn the
physician that is responsible for prescribing the medication to the consumer. 133 There
is no line drawn in Ohio that determines whether or not the information being provided
must be accurate but only that if the information is provided, the drug companies
cannot be held liable. 134
The Learned Intermediary Doctrine becomes an issue when specifically trying to
hold drug companies liable because they are able to pass along the liability. 135 In Tracy
v. Merrell Dow Pharmaceuticals Inc., the Ohio Supreme Court refused to allow
recovery for a death that resulted from nicotine chewing gum that was prescribed by
the family doctor.136 However, it also raised the question of what happens when these
drug companies engage in deceptive marketing tactics and the warnings are not
considered adequate. 137 The Ohio Supreme Court has yet to address an issue as to what
should happen when the warnings provided to the ‘learned intermediary’ are
inadequate. As shown by Attorney General DeWine, these pharmaceutical companies
have not been honest and forthcoming about the side effects that can, and almost
certainly will, arise from the long-term use of these prescription drugs.138 This is where
the need for accountability comes. An exception to the Learned Intermediary Doctrine
is needed because there were not adequate warnings being provided, and it has since
led to a nationwide epidemic. 139
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III. ANALYSIS
As the heroin epidemic continues to surge throughout the country, and specifically
in Ohio, the steps being taken by the government need to be more aggressive and
serious. Reaching agreements with drug pharmaceutical companies and allowing them
to pay only a fine, without requiring them to do something in return, is not enough. 140
As shown by the past, these pharmaceutical companies have entered into settlements
more than once but have still continued their deceptive practices. 141 The Learned
Intermediary Doctrine is being used to allow drug manufacturing companies to
absolve liability and place all of their liability on physicians. 142 To slow the epidemic,
there needs to be a way for states to hold the drug manufacturing companies liable.
Drug manufacturing companies are the main source of information regarding the
opioid drugs that the medical community is prescribing. 143 But, these same drug
manufacturing companies are also the primary source of funding for the CME
conferences as well as medical journals that were established and sent around for
physicians to spread information. 144 Now, in recognizing that there is a problem by
allowing these companies to fund everything, independent sources are coming forward
to do so as well as doctors’ offices and hospitals. They are agreeing to step away from
such close interactions with these companies.145
While this idea has been prompted in many states, the biggest question that arises
is, “who is going to pay for these continuing education programs?” 146 The next
question is, “why should tax payers be responsible for any charges brought where
these drug manufacturing companies have been using misleading and deceptive
schemes in order for them to make more money?” Among many settlement talks
happening surrounding several hundred opioid lawsuits, Federal Judge Dan Polster is
suggesting that the money from these settlements goes toward treatment for
individuals who have already been affected by this and to have doctors educated on
the effects of these drugs and ways to prescribe fewer of them. 147 While these
140
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settlement talks currently do not involve Ohio’s lawsuit versus the five big drug
companies, it would include several lawsuits that have been brought by cities and
municipalities in Ohio and involve the settlement money to be distributed in hopes of
helping people who are currently being affected by this epidemic. 148
A. The Solution: An Exception to the Learned Intermediary Doctrine
This epidemic is so widespread that it is time for something constructive to be
done.149 It is time to hold the correct people accountable, open up the ability to slow it
down, and get these severe issues under control. The reason this solution is the best is
because it goes to the root of the problem. The drug companies are responsible for
producing and making the drugs available to physicians as well as to consumers. 150 If
the deceptive marketing strategies are the same, it is going to be the sole responsibility
of the physicians to ensure that what they are being told by the drug representatives is
credible and in the best interest of the patients.151 Since there have only ever been
monetary settlements against these drug companies, some form of accountability
needs to attach to the companies.152 Part of this solution and promoting accountability
rests in educating the doctors the correct way, without the influence of the drug
companies, and encouraging safe practices in writing and delivering prescriptions.
Many states, including Ohio, have been reluctant to bring such a suit because it is
considered such a stretch to hold these companies liable, due to the Learned
Intermediary Doctrine.
This Note proposes that an exception to the Learned Intermediary Doctrine should
be introduced. Since the doctrine was originally established through case law, any
exceptions or abolishment of the doctrine will be able to be effectuated through case
law as well. Therefore, it is left up to the courts to settle this matter based on law suits
that are brought revolving around this issue.
This exception will include two prongs. The first prong will address whether a
drug manufacturing company is going to try and absolve itself from a duty owed to
consumers through the Learned Intermediary Doctrine. If the company should want to
use this, then they must be required to prove that they have done everything in their
power to stop the drugs from going to the black market. As stated earlier, diversion to
the black market is most common at the patient level. 153 Without providing the
information that is necessary to the medical community that is responsible for writing
these prescriptions, it can cause an influx of prescriptions, which then leads to these
drugs showing up on the black market. 154 When the drug manufacturing companies
are providing information to the medical community that these drugs are safe for longterm use, without leading to addiction, it can lead to the over-prescription of pain
148
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medication under the belief that it is safe to do so. 155 By enforcing this prong of the
exception, it will ensure that doctors are aware of their prescribing habits and are being
much more conscious to that respect because the information is being provided to them
directly from the drug representatives and the drug manufacturing companies.
Under this first requirement, this Note proposes that the duty should rest with the
drug manufacturers to provide information to the prescribing medical community on
how to responsibly prescribe opioids. The duty of a drug manufacturer cannot be
absolved if the information that is provided is knowingly wrong. Under this proposal,
the standard applied would be that of strict liability. For example, if the drug
manufacturing company is found to have been providing false or misleading
information, whether intentionally or not, they will not be able to utilize the Learned
Intermediary Doctrine as a defense. This will provide an another incentive to ensure
that the drug manufacturing companies are doing all that they can to conduct research,
educate, and inform their drug representatives and the medical community.
A second prong of this exception will include the requirement that drug
manufacturing companies fund continuing education programs for the medical
community to whom they provide information. Since the medical community that is
in charge of prescribing these opioid pain pills is relying on the information provided
from the manufacturers and their representatives, the only way to absolve the
manufacturer’s duty entirely is to provide another outlet for education. Part of this
education plan will be to include education for dealing with chronic pain and pain
management without the prescription of opioid pain killers. However, the
pharmaceutical companies will be required to bring in independent speakers, so as to
ensure they are not giving biased information. 156 As previously discussed, when the
pharmaceutical companies are bringing in their own KOLs, they are able to pay these
doctors as well as provide them with the information they want to be given out to
doctors. 157 This is further problematic because it gives an incentive for these doctors
to state opinions based on the amount of money they are being paid instead of what is
actually safe for the medical community and their patients. 158
If both of these prongs are adopted and accepted on a federal level as well as in the
state of Ohio, this will be the first of many successful steps towards effectively fighting
this epidemic.
While some may make the argument that you cannot completely eradicate drug
sales on the black market, my first prong would significantly decrease the diversion
because the drug companies and the medical community would be working together.
In previous years, it has been the drug companies providing information to the medical
community and the medical community acting in unison with that information. 159
However, with my first prong being implemented, it would promote true and correct
information as well as information that is in the best interest of the patients.
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B. The United States Supreme Court has the Authority to Make this Exception
Under federal law, the Learned Intermediary Doctrine provides the same defense
to liability that it does under Ohio law. A prescription drug manufacturer does not
have a legal duty to warn a consumer of the dangers of a drug as long as adequate
warning has been provided to the physician.160 Since the Supreme Court established
this doctrine under case law, the ability to abolish the doctrine or make changes to it
is also rests within the courts.
However, the Supreme Court has created several exceptions to this doctrine.
Specifically, the Court created an exception in Edwards v. Basel Pharmaceuticals, a
case where a man had a heart attack when he was wearing two nicotine patches. 161 The
widow of the man sued the pharmaceutical company that manufactured the nicotine
patch under products liability law. 162 The court in this case held that the Learned
Intermediary Doctrine did not apply because the manufacturers were required to
provide certain warnings to consumers of certain products. 163 The court further stated
that, the learned-intermediary doctrine should not be used to preclude liability, even if
the manufacturer had provided adequate warnings to the physician. 164 This ruling by
the Supreme Court should reflect overall rulings in products liability cases. If a drug
is believed to be one that carries such dangerous side effects that it requires the
manufacturer to ensure adequate warning has been given to the consumer, then the
manufacturing company should not be able to absolve liability by only providing
adequate warning to doctors.
C. The Role of the FDA
The FDA could also be responsible for allowing any changes to be made to the
doctrine. Since the FDA is the federal agency charged with consumer protection,
it is the front runner to be able to establish regulations for prescribing as well as
manufacturing prescription pain pills. 165 The FDA decides whether certain products
that will be used by consumers are safe for consumption and if any further regulation
needs to be created once the products are approved. 166 If the FDA enforced a regulation
on drug manufacturers that mandated the manufacturers to go further than just
providing adequate warnings to the physicians, then that would eliminate the Learned
Intermediary Doctrine altogether in these instances.
The FDA requires manufacturers of nicotine patches and/or nicotine gum to
provide adequate warnings not only to physicians but also to the consumers that will
be consuming the products. 167 If this were to be applied to prescription drug
manufacturers as well, then the drug manufacturers would be responsible for
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providing adequate warnings to consumers that could possibly be prescribed these
prescription drugs as well as the physicians that would be prescribing them. If this
were to be implemented, it would lead to a decrease in the number of drug related
deaths. While it may not happen overnight, and could take some time to develop, it is
ultimately encouraging and would result in a cost-benefit analysis that would come
out on the side of the consumer. This is what the FDA is charged with doing as the
only and oldest consumer protection agency within the United States Federal
Government.
D. The Ohio Supreme Court has the Authority to Make this Exception
The Ohio Supreme Court has made several adjustments to the overall application
of the Learned Intermediary Doctrine. 168 One exception, which is especially applicable
here, gives the defendant a chance to rebut the presumption of inadequate warning. 169
If the drug company can show that an adequate warning would not have made any
difference in how the physician decides to prescribe a drug, then proximate cause
cannot be met.170 In this case, the drug company will be absolved of liability for being
able to show that whether or not there was adequate warning given, it would have
made no difference. 171 The case that set out this exception is different from the current
Ohio lawsuit because the physicians were being told that there was no long-term
addiction consequences for prescribing these pain pills for chronic pain. 172 If these
physicians were aware of the addictive nature and the potential for addiction at the
time, it is a likely conclusion that they would have done things differently.
This is another way of showing how the Ohio Learned Intermediary Doctrine has
been expanded. Specifically, here, if the manufacturers are able to show the physicians
would not have done anything different, then the doctrine can apply. However, if they
are not able to do so, then the Learned Intermediary Doctrine should not apply, unless
the manufacturers are willing to accept responsibility by providing funding for CME’s
for physicians and taking the extra steps to ensure the physicians are properly and
adequately given information.
Another exception, in Vaccariello v. Smith & Nephew Richards Inc., the Ohio
Supreme Court expanded the Learned Intermediary Doctrine to include medical
devices as well as prescription drugs.173 The court reasoned that while the statute
specifically defines “ethical drug” and “ethical medical device” separately, there is no
indication based on the language of the doctrine itself, and it cannot apply to
prescription medical devices.174 This exception, however, was mainly an expansion of
the doctrine in favor of the drug companies, but the Ohio Supreme Court did not
extend any procedural protections as this note is suggesting. Even though the doctrine
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was expanded here, it was not in a substantive way, and therefore, the court could and
should still carve out the exception that this Note proposes.
In order to allow this solution, the Ohio Supreme Court would again have to find
that an exception is warranted. The court has expanded the Learned Intermediary
Doctrine and would be able to do so here because it is within the same scope of the
language. The court should expand the doctrine to include the exception that while the
drug may not be considered defective, in order for the learned intermediary doctrine
to apply, the manufacturer must have to show the steps they took.175
1.

Repealing The Learned Intermediary Doctrine

One possible counter argument to this proposed solution is: rather than creating an
exception to the learned intermediary doctrine, it could be repealed entirely. This
argument has been addressed but has not been accepted in jurisdictions nationwide, as
they all still follow and apply the Learned Intermediary Doctrine. 176
The rebuttal to this argument is the fact that this doctrine under products liability
law has been recognized nationwide, as well as on a state by state basis.177 Every state
has some form of the Learned Intermediary Doctrine under their products liability
law.178 Due to its extensive history, repealing this doctrine would be very difficult.
The Learned Intermediary Doctrine is also centered in protecting those manufacturers
who do in fact provide adequate warnings to consumers, as well as physicians, but
somewhere in the chain of communication, something is lost. It is not a bad doctrine
that needs to be repealed, but simply needs to be applied in a way that is ensuring the
right companies are being held liable and the right companies are being absolved of
liability. While this argument certainly makes sense given the context of this Note,
this would not be as successful because of the extensive legislative history given to
this doctrine and acceptance throughout the United States.
Another reason that appealing this doctrine would not be effective is because of
the new Direct to Consumer advertising (“DTC advertising”). DTC advertising is an
up and coming form of advertising that eliminates the need to warn physicians, which
would eliminate the need for the learned intermediary doctrine altogether. 179
2.

Punishment this Late would be Ineffective

Presumably, drug manufacturers might say that they should not be punished at this
point because the damage has already been done. Without any further negative acts
continuing to add to the problem, what is punishing them going to do? Also, it has
already been shown that at least one of the pharmaceutical companies involved in
Ohio’s lawsuit and several of the other state lawsuits, Purdue Pharma, has made
settlements with the federal government. 180 Purdue Pharma has also put a drug onto
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the market that is less-addictive than Oxycodone and has the same effect as far as pain
relief.181
Although these companies have already created the danger and it is living out in
society as we speak, there has yet to be a response from them. 182 While it is also in the
hands of the physicians and the medical community who prescribe these opioid pain
pills, in holding the drug companies liable for deceptive practices, it will force them
to act in a positive way. It will require them to ensure that the physicians and the
medical community they are in fact contacting are not prescribing in a way to allow
excess pills to end up on the streets or in the hands of addicts. 183 It will ensure that if
these physicians are to be held responsible and the duty falls to them, they are being
provided the adequate and correct information about what the effects of these opioid
pills have. 184 Furthermore, it will ensure that they be provided that information from
an independent third party. 185 Finally, CME programs are very relevant and necessary
in the medical community, but it is not reasonable to suggest taxpayers bear the burden
to fix a public health problem when it is caused by these billion dollar companies. 186
IV. CONCLUSION
There is no doubt that the Country as a whole is suffering from this severe and
debilitating epidemic. States like Ohio are complicated, deeply intertwined, and
continuing to get worse, not better. What is very clear within this ongoing epidemic,
is that something more needs to be done, and it needs to be sooner rather than later.
When large pharmaceutical companies are preying on consumers and their physicians
through deceptive tactics 187 and they are able to avoid the blame for their actions, 188
there needs to be consequences. These deceptive marketing practices not only led to
the opioid epidemic but have also been the background for rapidly increasing the
seriousness of the epidemic. This Note has discussed the ways that have already been
proposed, from allowing Narcan to be carried and bringing awareness to the epidemic.
Even after these proposals have been implemented though, they are still not successful
in stopping or even decreasing the amount of deaths from overdoses we are seeing
each and every year. With several states now realizing that the drug pharmaceutical
companies are at the core of this problem, more and more states are bringing law suits
against them in an attempt to hold them accountable.
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Since the learned intermediary doctrine was established through case law, 189 any
changes that can be made to it can be established through case law. This means that
exceptions can be carved out through case law under the United States Supreme
Court190 and the Ohio Supreme Court. 191 Also, because the Food and Drug
Administration is tasked with providing consumer protection, regulations could be laid
out that require drug manufacturers to warn consumers when there are specific drugs
that are being tested. Further, the FDA could establish the requirement that if the
warnings are not provided to the consumer, then the drug manufacturing company
could and will be held liable for any damages that result.
The answer to decreasing this serious drug epidemic across the nation is to hold
the pharmaceutical companies accountable and to not allow them to misplace the
blame. In making these companies understand the capacity of their deceptive
marketing to doctors and in turn to consumers, they will be forced to make changes
and to start to remedy their bad practices. This Note proposes a solution that would
require two separate actions from any company trying to use the Learned Intermediary
Doctrine. The first prong addresses when a drug manufacturing company is going to
try and absolve itself from a duty owed to consumers through the learned intermediary
doctrine. If the company should want to use this, then they must be required to prove
that they have done everything in their power to stop the drugs from going to the black
market. The black market is a hot spot for drug addicts to get their hands on drugs
illegally, and part of the reason behind this is due to the influx of illegal prescription
drugs into the black market. By ensuring proper prescription methods through giving
the physicians the information and knowledge they need, it is ensuring that less drugs
will illegally end up being sold on the black market and ultimately falling into the
wrong hands.
The second prong of this exception will include the requirement that drug
manufacturing companies fund continuing education programs for the medical
community to whom they provide the information. Since the medical community that
is in charge of prescribing these opioid pain pills is relying on the information provided
from the manufacturers and their representatives, the only way to absolve the
manufacturer’s duty entirely is to provide another outlet for education, instead of
allowing for the KOLs, which are paid for and provided by the manufacturing
companies themselves. This will ensure unbiased information as well as correct
information. Further, this will ensure that the consumer’s best interests are always the
first consideration.
It is never too late for a solution, and this would be a strong push in the direction
of showing the care for the consumers whose lives have been flipped upside down
because of the deceptive tactics. There needs to be a collective effort across all actors
involved in order to bring this to an end. Lives are being taken across all age ranges,
races, income levels, cities and rural areas, without any discrimination, and something
needs to be done. The proposals set out in this Note will begin to put an end to the
epidemic and be a giant step in the right direction toward slowing and ultimately
ending this awful epidemic.
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